Fighting a virus with a virus: a dynamic model for HIV-1 therapy.

A mathematical model examined a potential therapy for controlling viral infections using genetically modified viruses. The control of the infection is an indirect effect of the selective elimination by an engineered virus of infected cells that are the source of the pathogens. Therefore, this engineered virus could greatly compensate for a dysfunctional immune system compromised by AIDS. In vitro studies using engineered viruses have been shown to decrease the HIV-1 load about 1000-fold. However, the efficacy of this potential treatment for reducing the viral load in AIDS patients is unknown. The present model studied the interactions among the HIV-1 virus, its main host cell (activated CD4+ T cells), and a therapeutic engineered virus in an in vivo context; and it examined the conditions for controlling the pathogen. This model predicted a significant drop in the HIV-1 load, but the treatment does not eradicate HIV. A basic estimation using a currently engineered virus indicated an HIV-1 load reduction of 92% and a recovery of host cells to 17% of their normal level. Greater success (98% HIV reduction, 44% host cells recovery) is expected as more competent engineered viruses are designed. These results suggest that therapy using viruses could be an alternative to extend the survival of AIDS patients.

[1]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[2]  M. Nowak,et al.  Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.

[3]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[4]  A. Haase,et al.  Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. , 1999, Annual review of immunology.

[5]  S. Finke,et al.  A CXCR4/CD4 Pseudotype Rhabdovirus That Selectively Infects HIV-1 Envelope Protein-Expressing Cells , 1997, Cell.

[6]  J. Rose,et al.  Construction of a Novel Virus That Targets HIV-1-Infected Cells and Controls HIV-1 Infection , 1997, Cell.

[7]  J. Roughgarden,et al.  Theory of Population Genetics and Evolutionary Ecology , 1979 .

[8]  C. Rm.  Phage therapy: past history and future prospects. , 1999 .

[9]  J. Spouge,et al.  Quantifying the infectivity of human immunodeficiency virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Alan S. Perelson,et al.  Turnover of CD4+ and CD8+ T Lymphocytes in HIV-1 Infection as Measured by Ki-67 Antigen , 1998, The Journal of experimental medicine.

[11]  R Blumenthal,et al.  Quantitation of human immunodeficiency virus type 1 infection kinetics , 1993, Journal of virology.

[12]  E. Boritz,et al.  Requirement for a non‐specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus , 1998, The EMBO journal.

[13]  Andrew N. Phillips,et al.  Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response , 1996, Science.

[14]  A S Perelson,et al.  Modeling defective interfering virus therapy for AIDS: conditions for DIV survival. , 1995, Mathematical biosciences.

[15]  S. Wünschmann,et al.  Effect of coinfection with GB virus C on survival among patients with HIV infection. , 2001, The New England journal of medicine.

[16]  R. Siliciano,et al.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. , 2000, Annual review of immunology.

[17]  David Montefiori,et al.  An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants , 2001, Cell.

[18]  A. J. Hall.  Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[19]  J. Norris,et al.  Prokaryotic gene therapy to combat multidrug resistant bacterial infection , 2000, Gene Therapy.

[20]  M. Manns,et al.  Infection with GB virus C and reduced mortality among HIV-infected patients. , 2001, The New England journal of medicine.

[21]  B. Levin,et al.  Phage Therapy Revisited: The Population Biology of a Bacterial Infection and Its Treatment with Bacteriophage and Antibiotics , 1996, The American Naturalist.

[22]  A D Kelleher,et al.  A model of primary HIV-1 infection. , 1998, Mathematical biosciences.

[23]  D. Richman,et al.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. , 1999, Science.

[24]  R. Carlton,et al.  Phage therapy: past history and future prospects. , 1999, Archivum immunologiae et therapiae experimentalis.

[25]  G P Nolan,et al.  Harnessing Viral Devices as Pharmaceuticals: Fighting HIV-1's Fire with Fire , 1997, Cell.

[26]  M. Dabrowski,et al.  Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. , 1987, Archivum immunologiae et therapiae experimentalis.

[27]  A. McLean,et al.  Lifespan of human lymphocyte subsets defined by CD45 isoforms , 1992, Nature.

[28]  V. M. Sakandelidze.  [The combined use of specific phages and antibiotics in different infectious allergoses]. , 1991, Vrachebnoe delo.